Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Zentalis / ZN-c3-005

Trial Overview

Official Title

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN‑c3 (Azenosertib) in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 

Study Purpose

To evaluate the safety, clinical activity, and pharmacokinetics of ZN-c3 (also known as azenosertib) in subjects with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer 

Diagnosis

Platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Eligibility

1-4 prior lines of treatment, at least one line with bevacizumab.

Intervention

Oral ZN-c3 (Azenosertib). Treatment arms stratified by presence or absence of CCNE1/Cyclin E1 biomarkers.

For more information, go to the link below:

 

https://clinicaltrials.gov/study/NCT05128825?term=ZN-c3-005&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Female
Age
18 years and older
Enrollment Status
Suspended
Phase
Phase II
Methodist Health System Trial Code
ZN-c3-005